"Indans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.
| Descriptor ID |
D007189
|
| MeSH Number(s) |
D02.455.426.559.847.486.487 D04.615.486.487
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indans".
Below are MeSH descriptors whose meaning is more specific than "Indans".
This graph shows the total number of publications written about "Indans" by people in this website by year, and whether "Indans" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 0 | 1 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indans" by people in Profiles.
-
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 01; 32(5):954-962.
-
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. Inflamm Bowel Dis. 2026 Mar 01; 32(3):512-525.
-
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. Inflamm Bowel Dis. 2026 Jan 01; 32(1):77-86.
-
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. Am J Gastroenterol. 2025 Oct 01; 120(10):2339-2349.
-
Paternal preconception donepezil exposure enhances learning in offspring. Behav Brain Funct. 2024 Sep 28; 20(1):25.
-
Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
-
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease. Dig Dis Sci. 2024 Jun; 69(6):2044-2054.
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
-
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023 Dec 30; 17(12):2012-2025.
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.